Slideshow

Interesting T2DM: FDA News & Diabetes Risk

Author(s):

Julie Bowen

Our May list includes an app for titration of basal insulin, GI effects of GLP-1 agonists, and lifestyle intervention studies.

We present a selection of interesting news and research for the month of May focusing on type 2 diabetes. See the slide legends for links to the article summaries.

Related Videos
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
Related Content
A Pillared Approach: A Suite of THerapies for a Spectrum of Metabolic Disease
December 6th 2024

A Pillared Approach: A Suite of Therapies for a Spectrum of Metabolic Disease

Patrick Campbell
Diabetes Dialogue: News and Updates in Diabetes at AHA 2024
November 21st 2024

Diabetes Dialogue: News and Updates in Diabetes at AHA 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Endoscopy in the Age of GLP-1 RAs: 2024 Sees New Risk-Based Perioperative Guidance
December 4th 2024

Endoscopy in the Age of GLP-1 RAs: 2024 Sees New Risk-Based Perioperative Guidance

Abigail Brooks, MA
Diabetes Dialogue: Diabetes Tech Updates in October 2024
November 11th 2024

Diabetes Dialogue: Diabetes Tech Updates in October 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Obesity Drug MariTide Achieves Up to 20% Weight Loss in Phase 2 Trial | Image Credit: Amgen
November 26th 2024

Obesity Drug MariTide Achieves Up to 20% Weight Loss in Phase 2 Trial

Connor Iapoce
Dhruv Kazi, MD | Credit: PCSK9 Forum
November 18th 2024

More than 50% of US Adults Considered Eligible for Semaglutide with Current Labeling

Patrick Campbell
© 2024 MJH Life Sciences

All rights reserved.